Saturday 17 October 2026
Export AVBP’s income statement to Excel — free account
ArriVent BioPharma, Inc.
AVBP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16.7% and free cash flow fell 51.5%, each against the same quarter a year earlier.
16.66
0.13
−0.77%
Follow AVBP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(51.98%) | (58.88%) | (55.17%) | (53.10%) | |
| (48.90%) | (54.70%) | (51.43%) | (49.30%) | ||
ROIC |
(2,145.64%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.52%) | (54.18%) | (44.87%) | (44.70%) | |
Free Cash Flow per Share |
(3.49) | (4.18) | (2.98) | (3.11) | |
Free Cash Flow |
(146.08) | (160.59) | (134.47) | (147.93) | |
| Other line items | |||||
Cash ROIC |
(24.14%) | (25.90%) | (20.68%) | (19.99%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.96 | 0.97 | 0.93 | 0.90 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.49) | (4.18) | (2.98) | (3.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates